Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30965966 | 0.87 | NOS3 (0.47) | MAPK10HTR1AHTR7NOS3NOS2 | |
| SCHEMBL29498358 | 0.82 | MAPK10 (0.55) | MAPK10HTR1AHTR7NOS3NOS2 | |
| SCHEMBL29498359 | 0.82 | MAPK10 (0.55) | MAPK10HTR1AHTR7NOS3NOS2 | |
| SCHEMBL11269191 | 0.82 | MAPK10 (0.55) | MAPK10HTR1AHTR7NOS3NOS2 | |
| SCHEMBL29384557 | 0.81 | MAPK10 (0.55) | MAPK10NOS3NOS2MAOAMAPK14 | |
| SCHEMBL163051 | 0.81 | MAPK10 (0.55) | MAPK10NOS3NOS2MAOAMAPK14 | |
| SCHEMBL6769119 | 0.81 | NOS3 (0.53) | MAPK10NOS3NOS2MAOAMAPK14 | |
| SCHEMBL29498354 | 0.81 | MAPK10 (0.62) | MAPK10CHRNB4CHRNA3NOS3NOS2 | |
| SCHEMBL28341424 | 0.81 | MAPK10 (0.64) | MAPK10CHRNB4CHRNA3HTR1AHTR7 | |
| SCHEMBL28341380 | 0.81 | MAPK10 (0.62) | MAPK10CHRNB4CHRNA3NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149560-B1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-8846920-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846920-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846920-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1675929-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-06-22 | — | — | EP | disclosed |
| EP-1675929-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20100331506-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20070034863-A1 | fac-tris[7,7-difluoro-7H-dibenzo[de,h]quinoline-C2,N]iridium(III) (Ir1)A: 7,7-Difluorodibenzo[de,h]quinoline; use in organic electronic devices such as electroluminescent elements, and to their use in displays based thereon | UDC IRELAND LIMITED (IE) | 2007-02-15 | — | — | US | disclosed |
| US-20070034863-A1 | fac-tris[7,7-difluoro-7H-dibenzo[de,h]quinoline-C2,N]iridium(III) (Ir1)A: 7,7-Difluorodibenzo[de,h]quinoline; use in organic electronic devices such as electroluminescent elements, and to their use in displays based thereon | UDC IRELAND LIMITED (IE) | 2007-02-15 | — | — | US | disclosed |
| US-20070034863-A1 | fac-tris[7,7-difluoro-7H-dibenzo[de,h]quinoline-C2,N]iridium(III) (Ir1)A: 7,7-Difluorodibenzo[de,h]quinoline; use in organic electronic devices such as electroluminescent elements, and to their use in displays based thereon | UDC IRELAND LIMITED (IE) | 2007-02-15 | — | — | US | disclosed |
| EP-1675929-A1 | METAL COMPLEXES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033244-A1 | METAL COMPLEXES | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | MAPK10 3877/4885CHRNB4 223/4885CHRNA3 148/4885 |
| US-20100331506-A1 | METAL COMPLEXES | SOD1, AP1M1, AP2M1 | MAPK10 3381/4885CHRNB4 2056/4885CHRNA3 2215/4885 |
| US-20070034863-A1 | fac-tris[7,7-difluoro-7H-dibenzo[de,h]quinoline-C2,N]iridium(III) (Ir1)A: 7,7-Difluorodibenzo[de,h]quinoline; use in organic electronic devices such as electroluminescent elements, and to their use in displays based thereon | NISCH, CISD1, AFF1 | MAPK10 2809/4885CHRNB4 2238/4885CHRNA3 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.